Capital Planning Advisors LLC Purchases 31,530 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Capital Planning Advisors LLC lifted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 29.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 138,095 shares of the biotechnology company’s stock after acquiring an additional 31,530 shares during the period. Capital Planning Advisors LLC’s holdings in Heron Therapeutics were worth $304,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of HRTX. Nuveen LLC purchased a new stake in shares of Heron Therapeutics during the 1st quarter valued at $691,000. Invesco Ltd. boosted its holdings in shares of Heron Therapeutics by 67.6% in the 1st quarter. Invesco Ltd. now owns 119,662 shares of the biotechnology company’s stock worth $263,000 after buying an additional 48,263 shares during the last quarter. Deutsche Bank AG grew its position in Heron Therapeutics by 43.2% during the first quarter. Deutsche Bank AG now owns 85,610 shares of the biotechnology company’s stock valued at $188,000 after buying an additional 25,824 shares during the period. Headlands Technologies LLC increased its holdings in Heron Therapeutics by 260.5% during the first quarter. Headlands Technologies LLC now owns 92,558 shares of the biotechnology company’s stock worth $204,000 after buying an additional 66,886 shares during the last quarter. Finally, JW Asset Management LLC raised its position in Heron Therapeutics by 2.0% in the first quarter. JW Asset Management LLC now owns 2,337,743 shares of the biotechnology company’s stock worth $5,143,000 after acquiring an additional 45,325 shares during the period. Institutional investors own 80.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wall Street Zen cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. HC Wainwright started coverage on Heron Therapeutics in a research report on Monday, June 9th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, Needham & Company LLC decreased their price objective on shares of Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday.

Heron Therapeutics Stock Down 28.3%

HRTX opened at $1.32 on Monday. The business’s fifty day simple moving average is $2.00 and its 200 day simple moving average is $2.02. Heron Therapeutics, Inc. has a 52 week low of $1.04 and a 52 week high of $2.68. The stock has a market cap of $201.38 million, a PE ratio of -66.00 and a beta of 1.15.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Friday, August 8th. The biotechnology company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The firm had revenue of $37.20 million during the quarter, compared to analysts’ expectations of $38.08 million. As a group, equities analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.